In conclusion, our data demonstrate that combined HSCT-based macrophage-mediated GDNF gene therapy effectively delivers the therapeutic factor to sites of neurodegeneration and protects against loss of dopaminergic neurons and projection terminals in the MitoPark mouse model of PD, even when the intervention was initiated after the animals had manifested fully developed PD-like symptoms. This evidence concerns the gene GDNF and Parkinson disease.